| For: | Fernandez CJ, Shetty S, Pappachan JM. Diabetic cardiomyopathy: Emerging therapeutic options. World J Diabetes 2024; 15(8): 1677-1682 [PMID: 39192854 DOI: 10.4239/wjd.v15.i8.1677] |
|---|---|
| URL: | https://www.wjgnet.com/1948-9358/full/v15/i8/1677.htm |
| Number | Citing Articles |
| 1 |
L. A. Ruyatkina, D. S. Ruyatkin. Spectrum of effects of dipeptidyl peptidase-4 inhibitors: within and beyond glycemic control (part 1). Diabetes mellitus 2025; 28(4): 404 doi: 10.14341/DM13342
|
| 2 |
Francisco Epelde. Impact of DPP-4 Inhibitors in Patients with Diabetes Mellitus and Heart Failure: An In-Depth Review. Medicina 2024; 60(12): 1986 doi: 10.3390/medicina60121986
|
| 3 |
Xue Han, Zhuqi Huang, Guoxuan Liu, Yanan Liu, Weiqi Li, Jianing Zheng, Jie Tong, Mingyang He, Yurou Wu, Ze Li, Wu Luo, Qiaojuan Shi, Huazhong Ying, Guang Liang. VCPIP1 drives diabetic cardiomyopathy by deubiquitinating AMPKγ1 and preventing AMPKα-γ subunit assembly in cardiomyocytes. Signal Transduction and Targeted Therapy 2026; 11(1) doi: 10.1038/s41392-026-02701-9
|
| 4 |
Xiaofang Dan, Ke Li, Jiali Xu, Pijun Yan. The Potential of Neuregulin 4 as a Novel Biomarker and Therapeutic Agent for Vascular Complications in Type 2 Diabetes Mellitus. Journal of Inflammation Research 2024; : 8543 doi: 10.2147/JIR.S492115
|